nejm tirzepatide SURMOUNT-1 (NEJM 2022) tested — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants A 3-year study of tirzepatide
Description
This condition is remarkably common, affecting more than half of adults over age 60 in the United States
Extra fat cells act like mini chemical factories, releasing hormones and inflammatory messengers called cytokines, such as interleukin-6 (IL-6), Tumor necrosis factor alpha (TNF-alpha), interleukin-17 (IL-17), and others
In studies with rats, Mounjaro's active ingredient, tirzepatide, caused an increase in thyroid C-cell tumors
Does Ozempic Cause Bladder Infections
Wegovy Results (STEP-1 Trial) The STEP-1 trial examined 1,961 adults with obesity or overweight over 68 weeks
1133 Kato, Y
